Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

Next Previous
Search
Trial Profile

An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Bupropion; Caffeine; Dextromethorphan; Losartan; Midazolam; Modafinil; Omeprazole; Rosuvastatin
  • Indications Malignant melanoma; Skin cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Oct 2024 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Planned End Date changed from 30 Apr 2023 to 30 Jun 2023.
    • 24 Mar 2023 Results (n=10) reporting PK data presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top